A CD300LF affinity peptide and its application

CN122080130APending Publication Date: 2026-05-26HENAN CANCER HOSPITAL
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202610198666.5
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2026-02-11
Publication Date
2026-05-26

AI Technical Summary

Technical Problem

Existing intervention strategies targeting macrophage polarization rely on antibody drugs or small molecule inhibitors, which have problems such as limited targets, poor tissue penetration, systemic toxicity, and immune-related adverse reactions. There is an urgent need to develop new, safer, and more effective immune regulation methods.

Method used

We provide CD300LF affinity peptides that, through high affinity binding to the CD300LF protein, regulate macrophage function and enhance anti-tumor immune responses. This includes designing peptide probes for tumor diagnosis or tracking imaging and preparing drugs for the prevention and/or treatment of tumors.

Benefits of technology

CD300LF affinity peptides can effectively reprogram tumor-associated macrophages, reverse the immunosuppressive microenvironment, promote M1 polarization, and enhance the phagocytic capacity of macrophages for tumor cells, showing significant antitumor effects and immune activation. Furthermore, the modified peptides exhibit excellent in vivo stability and resistance to enzymatic degradation.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN122080130A_ABST
    Figure CN122080130A_ABST
Patent Text Reader

Abstract

This invention belongs to the field of biomedical technology, specifically disclosing a CD300LF affinity peptide and its applications. The CD300LF affinity peptide provided by this invention can specifically bind to the CD300LF protein and can be used to prepare peptide drugs or detection reagents targeting CD300LF, expanding the forms of drug / formulation development targeting CD300LF. Experiments have shown that the CD300LF affinity peptide can effectively reprogram tumor-associated macrophages, reverse the polarization of TAMs from M2 to M1, and promote the production of M1-related cytokines, thereby enhancing the phagocytic capacity of macrophages against tumor cells. The CD300LF affinity peptide provided by this invention exhibits significant tumor-suppressing effects and immune-activating effects in in vivo tumor models. Its modified peptide has excellent in vivo stability and anti-enzymatic degradation ability, and has no obvious toxic side effects, showing good prospects for translation and industrialization.
Need to check novelty before this filing date? Find Prior Art